Richard S. Finn, MD

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

Dr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

Richard S. Finn, an associate professor of medicine at the Geffen School of Medicine at the University of California, Los Angeles, discusses the FDA approval of abemaciclib (Verzenio) for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses both recent advances in the treatment of patients with liver cancer, as well as the future role that immunotherapy stands to have in this field.

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the challenges with determing a biomarker for patients with hepatocellular carcinoma (HCC) in an interview during the 10th Annual Conference of the International Liver Cancer Association (ILCA) in Vancouver, Canada. Finn is the current ILCA president.

Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma (HCC).

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.